An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial—an update to the published protocol-Reference-Cited by-同舟云学术

An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial—an update to the published protocol

Published:2024-07-05 Issue:1 Volume:25 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Randremanana Rindra Vatosoa,Raberahona Mihaja,de Dieu Randria Mamy Jean,Bourner Josephine^ORCID,Zadonirina Gabriella,Razananaivo Hanitra,Mayouya-Gamana Théodora,Mangahasimbola Reziky,Pesonel Elise,Gillesen Annelies,Rajerison Minoarisoa,Andrianaivoarimanana Voahangy,Edwards Tansy,Horby Peter,Olliaro Piero

Abstract

AbstractThis article reports an update to the protocol of the IMASOY trial, which was prospectively registered on clinicaltrials.gov (NCT04110340) in October 2019.

Funder

UK Foreign Commonwealth and Development Office and Wellcome

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s13063-024-08302-7.pdf

Reference3 articles.

1. Randremanana RV, Raberahona M, Randria MJD, Rajerison M, Andrianaivoarimanana V, Legrand A, et al. An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial. Trials. 2020;21(1):722.

2. World Health Organisation. Plague Outbreak Toolbox 2021. Available from: https://www.who.int/emergencies/outbreak-toolkit/disease-outbreak-toolboxes/plague-outbreak-toolbox.

3. Bourner J, Randriamparany R, Rasoanaivo TF, Denis E, Randremanana RV, Vaillant M, et al. Bubonic plague: can the size of buboes be accurately and consistently measured with a digital calliper? Trials. 2023;24(1):815.